Trials / Completed
CompletedNCT04438980
Glucocorticoids in COVID-19 (CORTIVID)
Treatment of COVID-19 Pneumonia With Glucocorticoids. A Randomized Controlled Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Fundacion Miguel Servet · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Around 30% of admitted patients with COVID-19 pneumonia develop a hyper-inflammatory state whose progression to an acute respiratory distress syndrome (ARSD) could be prevented by the early initiation of immune-modulatory agents. The role of glucocorticoids (GC) in this setting remains controversial. This study aims to assess the safety and effectiveness of GC pulses to improve the clinical outcomes of patients with COVID-19 pneumonia with risen inflammatory biomarkers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methylprednisolone | -A dose of 120 mg/day of methylprednisolone for 3 days, administered by intravenous infusión |
| OTHER | Placebo | -An infusion bag of 100 mL of 0.9% saline |
Timeline
- Start date
- 2020-05-15
- Primary completion
- 2021-03-12
- Completion
- 2021-04-09
- First posted
- 2020-06-19
- Last updated
- 2021-05-17
Locations
2 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT04438980. Inclusion in this directory is not an endorsement.